



EARTO Newsflash

IMI IP Policy and Funding Rate

FOR IMMEDIATE RELEASE

Brussels, 29 November 2010

EARTO and other IMI stakeholders published a joint statement on the Innovative Medicines Initiative in July 2010, asking for an urgent revision of the IMI IP policy and reimbursement rate (20% cap on indirect costs).

Last week, the IMI Joint Undertaking issued a guidance note on the IMI IP policy, which followed discussions of the IMI Intellectual Property Working Group. EARTO has taken note of this guidance document.

EARTO considers that this note contains some improvements and is a potentially useful document for newcomers to IMI, as it provides some explanations as to how IMI IP policy can be implemented in contract negotiations. However, the guidance note does not satisfactorily address the most critical IP issues identified by EARTO and many other stakeholders:

- reasonable definition of research use and of access rights for third parties;
- less extensive access rights for participants and affiliated entities worldwide, or at least better control of access rights by the owner;
- fair conditions for access (mandatory time limit for access, fair and reasonable terms rather than royalty free);
- and more balanced and reasonable conditions for licensing, assignment and other disposal of own assets, following the FP7 model (II.26.3 IMI GA).

The second issue identified by EARTO and other stakeholders in the Joint Statement from July 2010 – the 20% cap on indirect costs – has not been addressed. EARTO would like to see this cap lifted as a matter of priority.

EARTO is consulting with other signatories of the Joint Statement from July 2010 to see if a joint response can be adopted.

END

For further information, please contact Pauline Bastidon, EARTO Policy Officer:
+32 (0)2 502 86 98 – bastidon@earto.eu



Notes to editors:

Joint Statement on the Innovative Medicines Initiative, July 2010:

http://www.earto.eu/fileadmin/content/13_Media/IMI_Statement_withLOGOs.pdf

IMI IP guidance note:

http://www.imi.europa.eu/sites/default/files/uploads/documents/Intellectual%20Property/GuidanceNote_Draft3-1_10Nov2010.pdf

IMI

The Innovative Medicines Initiative is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission. Launched in 2007, IMI aims to support more efficient discovery and development of better medicines for patients by removing research bottlenecks in the current drug development process. The total IMI budget for the period 2008-2017 is €2 billion (1 billion from the European Community and 1 billion from the industry).

http://imi.europa.eu/index_en.html

EARTO

EARTO is the European trade association of the research and technology organisations (RTOs), a non-profit organisation founded in 1999. EARTO groups over 350 RTOs, with a combined staff of 150,000, an annual turnover of €15 Billion, special equipment and facilities to a value of many € billions and more than 100,000 customers from the public and private sectors annually.

<http://www.earto.eu>